The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.
about
Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanasePG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelA novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesisMechanisms of heparanase inhibitors in cancer therapy.A heparin mimetic isolated from a marine shrimp suppresses neovascularization.Assessment of Heparanase-Mediated Angiogenesis Using Microvascular Endothelial Cells: Identification of λ-Carrageenan Derivative as a Potent Anti Angiogenic AgentChemical Tumor Biology of Heparan Sulfate Proteoglycans.PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical modelsHypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesThe role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus.Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival.The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineHeparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancerHeparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activationHeparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasisThe Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles.Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applicationsAntitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.Heparan sulfate in angiogenesis: a target for therapy.The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.MicroRNA regulation of proteoglycan function in cancer.The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 ExpressionHeparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.Targeting heparin and heparan sulfate protein interactions.Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.Heparanase: From basic research to therapeutic applications in cancer and inflammation.Heparin Mimetics: Their Therapeutic Potential.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.Cancer Cell Glycocalyx and Its Significance in Cancer Progression
P2860
Q24605311-BA6FC912-32A9-44DB-8608-2A3AD4A5422BQ27327191-AECA71BF-B599-4EE7-97A6-CD0D0FC6DE69Q28476695-38A5D753-D54F-4F13-B476-5A8D3EB7A427Q30244089-E70F17E9-F40C-4AF3-8823-9177D889C151Q33584177-47411F65-92F6-4F94-B400-2BD8D00D6321Q33744134-F301E125-FE38-4806-A18F-58935A3FEC89Q33944132-96B5B6B5-2D70-4A98-88DF-D4943FC490DBQ34627931-3F67408E-94BB-493D-BF51-48F696C37C59Q35341540-D6AA11CB-2344-4513-80A3-B2FE1A71DFAAQ35470322-26E4E19B-A5B1-4D0D-820F-3E1C69B51249Q35651533-61EED83D-C382-4DCB-9BD5-42AB12A0AD78Q35659513-585BCC87-DCD2-4088-8540-301BB1D32273Q35741596-9508EC0D-0F5A-4D9E-9152-3F829077F8D4Q35838889-8BC8A6A4-0D1A-4138-B462-8EDF31C3E0F5Q36430711-D89CCEB9-87D1-47A3-91C5-AE4948E78C19Q36498218-8A5B8BBC-5205-4558-8378-C354F275901EQ36571976-02E99DD6-5B5D-4885-A5D3-276B42462BA1Q36919158-3EC3ACF4-0E8E-4C7B-A1F7-9B7A708988ADQ37565298-8C7E1679-9DFA-4688-A9CB-87E43852925CQ38154506-4F3B09E5-43A4-449F-996F-D87EC4FA7385Q38238094-444FAB63-5D75-42C8-B0D4-1D06F007CBDBQ38244283-C0163309-F4DC-4288-9A7D-E08501415FB1Q38718475-03CE0C85-3B8C-4FC5-8241-083FC31D2BC3Q38801721-871B29BC-961B-49F5-BCA3-0A59A726D195Q39270408-F74B9544-CFA0-4DAB-BA26-8A9CED919173Q39399937-502A60F7-FA28-4CC9-9B9D-D2C003A3BC8FQ41817665-55C9804B-E15F-46BC-8332-37CA8BE3A272Q42587945-B3DCF40E-8154-4F06-A1D5-190D1534AC24Q47159791-D95383E0-76E6-41A5-8D54-1C8796947229Q48171089-533F7A35-CFBB-4FC9-8200-8D8CABE8B24CQ52659459-B7A47FBC-BAC9-4A85-839B-8F6F6B4CA0AFQ55414494-AD12ED02-4453-4DB0-98A7-9E17BDE102BCQ57168005-CA537CFC-9BFE-4950-B358-09DF521A842A
P2860
The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@en
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@nl
type
label
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@en
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@nl
prefLabel
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@en
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@nl
P2093
P1476
The PG500 series: novel hepara ...... inhibitors for cancer therapy.
@en
P2093
I Bytheway
K Johnstone
P2888
P304
P356
10.1007/S10637-009-9245-5
P577
2009-04-09T00:00:00Z